{"entity":{"id":"bdc-4182","kind":"drug","name":"BDC-4182","aka":[],"tldr":"BDC-4182 is an experimental monoclonal antibody from Bolt Biotherapeutics in phase 2 trials for gastric & gastro-oesophageal junction cancer, aimed at Claudin 18.2.","summary":"BDC-4182 is a monoclonal antibody developed by Bolt Biotherapeutics. Its target is Claudin 18.2 (the sponsor names Claudin 18.2). The sponsor states: A 'Boltbody' immune-stimulating antibody conjugate (ISAC) combining an anti-Claudin 18.2 monoclonal antibody with a TLR7/8 dual agonist, working through immune activation (inducing immunological memory) rather than direct cytotoxicity. ClinicalTrials.gov describes the intervention as: Immune stimulating antibody conjugate (ISAC), consisting of an anti-claudin 18.2 monoclonal antibody conjugated to a TLR 7/8 dual agonist. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in gastric & gastro-oesophageal junction cancer. The largest, NCT06921837, plans to enrol 122 participants with primary completion expected 2027-05. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of BDC-4182","url":"https://clinicaltrials.gov/search?intr=BDC-4182"},{"label":"Sponsor pipeline page","url":"https://boltbio.com/pipeline/"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":["cldn18-2"],"drugs":[],"companies":["bolt-biotherapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06921837"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"monoclonal antibody","mechanism":"A 'Boltbody' immune-stimulating antibody conjugate (ISAC) combining an anti-Claudin 18.2 monoclonal antibody with a TLR7/8 dual agonist, working through immune activation (inducing immunological memory) rather than direct cytotoxicity.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/bdc-4182/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"target":[{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/"}],"company":[{"id":"bolt-biotherapeutics","kind":"company","name":"Bolt Biotherapeutics","route":"/companies/bolt-biotherapeutics/"}],"trial":[{"id":"nct06921837","kind":"trial","name":"A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer","route":"/trials/nct06921837/"}]}}